Brokerages Set Celcuity Inc. (NASDAQ:CELC) Target Price at $30.17

Celcuity Inc. (NASDAQ:CELC) has been given a consensus rating of “Buy” by the seven ratings firms that are covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $30.17.

Several research analysts recently commented on CELC shares. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Needham & Company LLC raised their price target on shares of Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, February 6th.

Celcuity Price Performance

NASDAQ:CELC opened at $10.64 on Wednesday. The firm has a market cap of $395.06 million, a price-to-earnings ratio of -4.08 and a beta of 0.73. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The company’s 50-day moving average is $11.77 and its two-hundred day moving average is $13.59. Celcuity has a 12-month low of $8.53 and a 12-month high of $22.19.

Institutional Trading of Celcuity

A number of large investors have recently bought and sold shares of the stock. Soleus Capital Management L.P. boosted its stake in Celcuity by 106.0% in the fourth quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company’s stock worth $33,577,000 after purchasing an additional 1,319,700 shares in the last quarter. Baker BROS. Advisors LP boosted its stake in Celcuity by 42.9% in the fourth quarter. Baker BROS. Advisors LP now owns 2,678,553 shares of the company’s stock worth $35,062,000 after purchasing an additional 803,575 shares in the last quarter. State Street Corp boosted its stake in Celcuity by 152.2% in the third quarter. State Street Corp now owns 1,107,415 shares of the company’s stock worth $16,512,000 after purchasing an additional 668,318 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Celcuity in the fourth quarter worth $8,468,000. Finally, Braidwell LP boosted its stake in Celcuity by 71.2% in the third quarter. Braidwell LP now owns 884,306 shares of the company’s stock worth $13,185,000 after purchasing an additional 367,663 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.